Changes in Hong Kong stocks | CSPC Group (01093) rose more than 6%, and clinical trial application for ActriIA/b antibody JMT206 injection approved

Zhitongcaijing · 11/26/2025 01:57

The Zhitong Finance App learned that CSPC Group (01093) rose by more than 6%. As of press release, it had risen 6.56% to HK$8.27, with a turnover of HK$314 million.

According to the news, on November 25, CSPC Group's clinical trial application for ActriIA/b antibody JMT206 injection was approved for the treatment of obesity. According to reports, in November of this year, Shiyao Group disclosed pre-clinical research data for jMT206 on ObesityWeek. jmt206 is a potent ActriIA/b antibody. IC50 that blocks ActRiIA/b activation induced by Actvin A, GDF8, and GDF11 is at the PM level, and also has cross-activity between human, monkey, rabbit, rat, and mouse genera. Mice gained 8.12%-22.12% in 3 weeks of treatment. Weight gain is associated with increased muscle gain. Reduces muscle loss, and the bioavailability of subcutaneous injections in monkeys is 65%.